Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidoglycan (PGN) and lipoteichoic acid (LTA) are the primary structural and functional constituents of the Gram-positive bacterial cell wall. Peptidoglycan is a complex heteropolymer of sugars and amino acids that forms a mesh-like layer, providing the cell with essential structural integrity and protection against high internal osmotic pressure (Schleifer & Kandler, 1972). Lipoteichoic acid is a surface-associated glycerolphosphate polymer anchored to the plasma membrane that plays critical roles in regulating autolytic enzymes, maintaining ion homeostasis, and facilitating biofilm formation (Percy & Gründling, 2014). These molecules are recognized by the host's innate immune system as pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors like Toll-like receptor 2 (TLR2) and NOD-like receptors, which initiate inflammatory signaling cascades (Kang et al., 2009). Clinically, these components are the direct targets of several potent antibiotic classes; for example, glycopeptides such as vancomycin bind to the D-alanyl-D-alanine terminus of peptidoglycan precursors to prevent cross-linking, while lipopeptides like daptomycin are thought to interact with lipoteichoic acid to facilitate membrane insertion and subsequent depolarization (Bayer et al., 2013). Excessive release of PGN and LTA during severe infections can lead to systemic inflammatory response syndrome and septic shock (Ginsburg, 2002).
Inhibition of cell wall synthesis by binding to peptidoglycan precursors (D-Ala-D-Ala); disruption of bacterial cell membrane potential through interaction with lipoteichoic acid and membrane lipids; enzymatic hydrolysis of glycan bonds.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidoglycan and lipoteichoic acid (PGN and LTA).